4//SEC Filing
Mims David W. 4
Accession 0001437749-20-013677
CIK 0000835887other
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 4:48 PM ET
Size
8.1 KB
Accession
0001437749-20-013677
Insider Transaction Report
Form 4
Mims David W.
10% OwnerOther
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−16,393→ 0 totalExercise: $5.01Exp: 2029-12-13→ Common Stock (16,393 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−40,000→ 0 totalExercise: $5.01Exp: 2029-12-13→ Common Stock (40,000 underlying)
Footnotes (2)
- [F1]On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect.
- [F2]This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger.
Documents
Issuer
PROGENICS PHARMACEUTICALS INC
CIK 0000835887
Entity typeother
Related Parties
1- filerCIK 0001789675
Filing Metadata
- Form type
- 4
- Filed
- Jun 22, 8:00 PM ET
- Accepted
- Jun 23, 4:48 PM ET
- Size
- 8.1 KB